Mateon Therapeutics to Present Data on Study OX4218 in Neuroendocrine Tumors at ASCO Gastrointestinal Cancers Symposium
January 20, 2017 08:00 ET
|
Mateon Therapeutics
- Data Shows Additional Evidence of CA4P Activity -- Investigator-sponsored Study Initiating, Based on OX4218 Results - SOUTH SAN FRANCISCO, Calif., Jan. 20, 2017 (GLOBE NEWSWIRE) -- Mateon...
Mateon Common Stock to Trade on OTCQX Beginning on December 8, 2016
December 07, 2016 10:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
Mateon Announces Presentation of OXi4503 AML Study Data at 58th Annual Meeting of American Society of Hematology
December 06, 2016 07:00 ET
|
Mateon Therapeutics
- Completed enrollment in the two lowest dose cohorts, third cohort now in progress - - Patients had on average failed 4 prior therapies - - Across the first two cohorts, 20% of patients...
Mateon Provides Corporate Update and Reports Third Quarter 2016 Financial Results
November 14, 2016 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
Mateon Announces Adjournment of Special Meeting of Stockholders
November 11, 2016 18:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
Mateon Announces Presentation of CA4P Posters at Meeting of the International Gynecologic Cancer Society
October 31, 2016 08:30 ET
|
Mateon Therapeutics
- Patients with Measurable Disease Showed Significantly Improved Progression-Free Survival - - Progression-Free Survival Improved by 6.2 Months for Patients with Larger Tumors - SOUTH SAN...
Mateon Expands Board of Directors with the Appointments of Donald R. Reynolds and Bobby W. Sandage, Jr., Ph.D.
October 27, 2016 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
Mateon Announces Issuance of US Patent for Cathepsin Inhibition
October 10, 2016 08:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
Mateon Announces Collaboration with US Oncology Research to Participate in Phase 2/3 FOCUS Study
September 26, 2016 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
Mateon Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
September 20, 2016 15:45 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a clinical-stage biopharmaceutical company developing vascular disrupting agents for the...